PD50-01 PROSTERIA: A CLAIMS-BASED STUDY OF DEMOGRAPHIC AND TEMPORAL TRENDS IN FREQUENT PROSTATE SPECIFIC ANTIGEN TESTING

Abstract

You have accessJournal of UrologyProstate Cancer: Detection & Screening V (PD50)1 Sep 2021PD50-01 PROSTERIA: A CLAIMS-BASED STUDY OF DEMOGRAPHIC AND TEMPORAL TRENDS IN FREQUENT PROSTATE SPECIFIC ANTIGEN TESTING Dylan Peterson, Shufeng Li, Hriday Bhambhvani, James Brooks, and Michael Eisenberg Dylan PetersonDylan Peterson More articles by this author , Shufeng LiShufeng Li More articles by this author , Hriday BhambhvaniHriday Bhambhvani More articles by this author , James BrooksJames Brooks More articles by this author , and Michael EisenbergMichael Eisenberg More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002072.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: While there is disagreement between professional medical organizations about which patients should undergo Prostate Specific Antigen (PSA) screening, there are no guidelines that recommend PSA screening more often than annually. Despite this, there are patients who have their PSA tested more frequently, which we have termed “Prosteria”. We aimed to characterize patient demographic and temporal trends of frequent PSA testing. METHODS: Adult men with at least three PSA tests and two or more years of continuous insurance enrollment in the Optum De-identified Clinformatics® Data Mart were included in this study. Men were censored at the end of their insurance enrollment or 30 days prior to a diagnosis of prostate cancer, prostatitis, or UTI. PSA tests were excluded if they occurred within 30 days of a prior PSA test. “High frequency PSA testing” was defined as an average of one or more PSA tests every 9 months. Multivariable logistic regression evaluated associations between demographic features and PSA testing frequency. RESULTS: 9,547,876 PSA tests obtained between January 2003 and June 2019 on 1,996,472 men were included. While 55% of men were tested less than annually, 19% of men underwent high frequency testing. The distribution of time between PSA tests was notable for spikes around 90, 180, and 365 days. Patients were less likely to undergo high frequency testing if they were White (OR: 0.73, 95% CI: [0.72, 0.73]), educated (OR: 0.91, 95% CI: [0.91, 0.92]), and younger (OR: 0.98 per year, 95% CI: [0.97-0.98]). However, a U-shaped distribution was observed with men aged 55-65 being less likely to undergo high frequency testing than younger or older men. Of men with PSA levels available, men with high frequency testing had higher average PSA values (1.99 (SD: 1.94) vs 1.31 (SD: 1.30); p < 0.001). Over the study period, the proportion of patients getting high frequency testing increased at a rate of 1.17% per year (figure). CONCLUSIONS: In this large cohort study, high-frequency PSA testing was common, increasing over time, and significantly associated with demographic characteristics. Future work will investigate variations between ordering providers based on geographic region and specialty, as well as the impact of screening frequency on rates of prostate biopsy, cancer detection and treatment. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e851-e851 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dylan Peterson More articles by this author Shufeng Li More articles by this author Hriday Bhambhvani More articles by this author James Brooks More articles by this author Michael Eisenberg More articles by this author Expand All Advertisement Loading ...